Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00795821 · ClinicalTrials.gov registry record · Phase 2
A Study in Adult Patients With Major Depressive Disorder
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 495
- Enrollment target
NCT00795821: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00795821 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 495 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (272% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00795821, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 495 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.
Primary Outcome
The MADRS measured severity of depressive mood symptoms. The 10-item checklist rating scale was 0 to 6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Means were adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.
Interventions
- DRUG Placebo
- DRUG LY2216684
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
What the finished NCT00795821 record still lists
NCT00795821 is an interventional study that assigns participants to a tested intervention. The registered 495 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (272% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00795821 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00795821 about?
NCT00795821 is a clinical study titled "A Study in Adult Patients With Major Depressive Disorder". The purpose of this study is to assess whether LY2216684 is superior to placebo in the treatment of adult patients with major depressive disorder.
What is the current status of trial NCT00795821?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 495 participants. The study started on 2008-12. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00795821?
The interventions under investigation include: Placebo (DRUG), LY2216684 (DRUG).
Who is sponsoring clinical trial NCT00795821?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00795821's enrollment target sits among peer trials
495 76th of 2000 higher than 1,925 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03127267 · 495 participants · Phase 3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
- NCT06400472 · 495 participants · Phase 1
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
- NCT05283720 · 496 participants · Phase 2
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
- NCT06417775 · 496 participants · Phase 3
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia